Headquarters: Bratislava, Slovak Republic
Founded: 2010
Type: Clinical-stage biotechnology company
Website: axon-neuroscience.eu
Axon Neuroscience SE is a Czech-Slovak biopharmaceutical company dedicated to developing disease-modifying therapeutics targeting tau pathology in Alzheimer's disease and other neurodegenerative disorders. The company's lead product, AADvac1, is a novel active immunotherapy (therapeutic vaccine) that stimulates the immune system to produce antibodies against pathological tau proteins. Axon represents one of the most advanced efforts to translate tau immunotherapy from preclinical success to clinical reality[1][2].
Unlike passive monoclonal antibody approaches, AADvac1 is an active vaccine that generates a polyclonal antibody response against pathological tau. This approach offers potential advantages in terms of durability, cost, and broader epitope coverage. The company is currently evaluating AADvac1 in both Alzheimer's disease (Phase 2) and as part of the PSP Clinical Trial Platform[3][4].
Axon's platform is based on therapeutic vaccination — administering tau-derived peptide antigens conjugated to a carrier protein (keyhole limpet hemocyanin, KLH) to stimulate active antibody production in patients:
The AADvac1 antigen is designed to selectively target pathological tau while sparing normal physiological tau:
AADvac1 (also styled as AADvac1 or AAD-vac1) is Axon's lead candidate and one of the most advanced active tau immunotherapies in clinical development.
| Attribute | Details |
|---|---|
| Mechanism | Active immunotherapy (tau vaccine) |
| Antigen | Tau-derived peptide-KLH conjugate |
| Target | Pathological tau aggregates |
| Indication | Alzheimer's disease, PSP |
| Development Stage | Phase 2 |
NCT02773758: The ADAMANT study was a randomized, placebo-controlled Phase 2 clinical trial evaluating AADvac1 in patients with mild Alzheimer's disease[4:1].
Key findings from ADAMANT:
Biomarker evidence: Studies in treated patients showed reduced tau seeding activity in cerebrospinal fluid, suggesting target engagement of pathological tau species[6].
AADvac1 has been selected as one of the first investigational products in the PSP Clinical Trial Platform (NCT07173803) at the University of Pennsylvania[3:1]:
Rationale for PSP: The absence of amyloid pathology in PSP makes it an ideal setting to test pure tau-targeting approaches. If AADvac1 demonstrates efficacy in PSP, it would support the broader hypothesis that tau immunotherapy can modify disease progression in tauopathies[7].
Axon maintains an active pipeline of next-generation tau immunotherapies:
| Program | Target | Indication | Stage |
|---|---|---|---|
| AADvac2 | Tau (optimized) | AD, PSP | Preclinical |
| Axon Tau Biomarker Program | N/A | Companion diagnostics | In development |
The tau protein plays essential roles in neuronal cytoskeletal stability under normal conditions. In Alzheimer's disease, PSP, and related tauopathies, tau becomes hyperphosphorylated, misfolds, and aggregates into toxic species:
The correlation between tau pathology burden and cognitive decline is stronger than that for amyloid pathology, making tau an attractive therapeutic target[8].
Active tau immunotherapy has several theoretical advantages over passive monoclonal antibodies:
However, active immunotherapy also has limitations:
Axon Neuroscience was founded by leading Slovak neuroscientists with expertise in tau biology and vaccine development:
The company holds a broad patent portfolio covering:
AADvac1 competes in the tau immunotherapy space with both active and passive approaches:
| Company | Product | Type | Indication | Stage |
|---|---|---|---|---|
| Axon Neuroscience | AADvac1 | Active vaccine | AD, PSP | Phase 2 |
| Janssen/AC Immune | ACI-35.030 | Active vaccine (liposome) | AD | Phase 2 |
| Roche/Genentech | Semorinemab | Passive mAb | AD, PSP | Phase 2 (failed) |
| Biogen | BIIB080 | ASO | AD, PSP | Phase 1/2 |
| AbbVie | Tilavonemab | Passive mAb | PSP | Phase 2 (failed) |
The distinction between active vaccines (AADvac1, ACI-35.030) and passive antibodies is a key differentiator. Active approaches require the patient's immune system to generate antibodies, while passive approaches deliver antibodies directly.
NovaKova M, et al. AADvac1 Phase 2 results in Alzheimer's disease. Nat Aging. 2022. ↩︎ ↩︎
Kontsekova E, et al. First Alzheimer disease vaccine using tau epitope. Lancet Neurol. 2016. ↩︎
Kovacs GG, et al. Tau seeding activity in brain tissue from AADvac1-treated patients. Acta Neuropathol. 2022. ↩︎
Singh S, et al. Active tau immunization in 4R-tauopathies. Neurobiol Dis. 2023. ↩︎
Telcheva M, et al. Tau immunotherapy: progress and challenges. Nat Rev Neurol. 2023. ↩︎
NovaKova M, et al. AADvac1, a novel therapeutic vaccine targeting pathological tau protein. Expert Opin Ther Pat. 2018. ↩︎